Research programme: thymidylate synthase inhibitors - Sarissa
Alternative Names: SARI-083Latest Information Update: 04 Nov 2017
At a glance
- Originator Isis Pharmaceuticals
- Developer Sarissa
- Class Antisense oligonucleotides
- Mechanism of Action Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Canada
- 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
- 14 Feb 2011 The lead compound from the programme, SARI 083, is in active development in Canada